Nasal sprays are used to locally or systemically provide drugs to the nasal cavities. They are applied locally to treat problems such as allergic rhinitis and nasal congestion. When a medicine is administered nasally, it is absorbed via the nasal mucosa rather than entering the respiratory tract. It is marketed as a different, non-invasive route that may be utilized for both local and systemic therapy and is particularly helpful when dealing with medications that are highly metabolized or unstable in the GI (gastrointestinal) medium.
US Nasal Spray Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 610 million cases and 6.51 million deaths due to coronavirus (COVID-19) were reported till September 22, 2022, across the globe.
Impact of COVID-19 on Demand and Supply of Nasal Spray
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
However, the COVID-19 pandemic has increased research and development for the use of nasal spray for the treatment and prevention of coronavirus infection. This is assisting in the market growth, which is expected to boost the U.S. nasal spray market growth over the forecast period. For instance, in 2021, scientists at the University of Pennsylvania and Regeneron, a biotechnology company, announced that they were collaborating and investigating whether technology developed for Adeno-Associated Virus (AAV) gene therapy can be used to make a nasal spray that will prevent infection with the new coronavirus.
US Nasal Spray Market is estimated to be valued at US$ 9,272.8 Mn in 2022, and is expected to exhibit a CAGR of 6.8% over the forecast period (2022-2030).
Figure 1: U.S. Nasal Spray Market Share (%) Analysis, By Type, 2022
Increasing incidence of allergic rhinitis is expected to drive growth of market over the forecast period.
Increasing incidence of allergic rhinitis is expected to fuel growth of the U.S. nasal spray market over the forecast period. For instance, according to Asthma and Allergy Foundation of America, in the U. S., seasonal allergic rhinitis was diagnosed in about 24 million people in 2018 (hay fever) which includes 8% (19.2 million) of adults and 7% (5.2 million) of children. In 2018, compared to black children, white children showed a higher prevalence of hay fever.
|Base Year:||2021||Market Size in 2022:||US$ 9,272.8 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||6.8%||2030 Value Projection:||US$ 15,723.5 Mn|
GlaxoSmithKline plc, Sanofi S.A., Bayer AG, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., Procter & Gamble, AstraZeneca Plc., NeilMed Pharmaceuticals Inc., Church & Dwight Co., Inc., and Neurelis, Inc
|Restraints & Challenges:||
Figure 2: U.S. Nasal Spray Market Value (US$ Mn) Analysis and Forecast and Y-o-Y Growth (%), 2017-2030
Advantages of using nasal sprays are expected to boost the U.S. nasal spray market growth over the forecast period.
There are various benefits of using nasal route of administration and nasal sprays for drug delivery, this is expected to fuel the U.S. nasal spray market growth over the forecast period. Benefits of using saline nasal sprays include –
Restraint- US Nasal Spray Market
Due to regulatory standards not being met, market players are recalling their nasal sprays. This is expected to hinder growth of the U.S. nasal spray market over the forecast period. The following products were recalled:
US Nasal Spray Market – Competitive Landscape
Major players operating in the U.S. nasal spray market are GlaxoSmithKline plc, Sanofi S.A., Bayer AG, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., Procter & Gamble, AstraZeneca Plc., NeilMed Pharmaceuticals Inc., Church & Dwight Co., Inc., and Neurelis, Inc.
A nasal spray is a medication that is sprayed into the nostril in a fine mist from a container. Nasal sprays are used locally to treat problems such as nasal congestion and allergic rhinitis. In some cases, the nasal delivery route is used for systemic therapy since it is a more pleasant alternative to injections or pills. When ingested directly through the nose, substances can be absorbed very quickly.
Increase in number of acquisitions between market players is expected to boost the U.S. nasal spray market growth over the forecast period. For instance, in October 2018, Emergent BioSolutions, a U.S. based biopharmaceutical company announced acquisition of Adapt Pharma, a pharmaceutical company, developing therapeutic treatments for patients with special medical conditions and its flagship product NARCAN (naloxone HCl) Nasal Spray. NARCAN (naloxone HCl) is first and only intranasal form of naloxone approved by the U.S. Food and Drug Administration (FDA) and Health Canada, for the emergency treatment of known or suspected opioid overdose.
Increasing number of product launches by market players are expected to bolster growth of the U.S. nasal spray market. For instance in December 2021, Sandoz, a global company in generic and biosimilar medicines, announced the launch of its authorized generic Narcan (naloxone hydrochloride) Nasal Spray 4mg in the U.S. indicated to reverse opioid overdose. People in the U.S. can buy it from retail pharmacies and other facilities, like hospitals.
Market players are engaged in nasal spray launching in U.S. are expected to drive growth of market over the forecast period. For instance, on August 31 2022, Glenmark Pharma, a multinational pharmaceutical company, launched Ryaltris nasal spray for allergic rhintis in the U.S. It will be distributed by Hikma Pharmaceuticals, a British Pharmaceutical company in the US. Ryaltris is the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the US market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients